2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center and professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the efficacy of entospletinib plus obinutuzumab (Gazyva) in relapsed/refractory chronic lymphocytic leukemia (CLL).
During the 2021 International Workshop on CLL, the final results of a phase 1/2 trial (NCT03010358) were presented, evaluating entospletinib, an investigational SYK inhibitor, in combination with obinutuzumab in patients with relapsed/refractory CLL. At a median follow-up of 31 months, the findings demonstrated an overall response rate (ORR) of 67% among 21 patients with CLL treated with the doublet, Danilov says. The ORR comprised 3 complete responses (CRs) and 11 partial responses. The median event-free survival was 27.5 months.
Notably, the majority of patients (62%) included on the study had high-risk cytogenetics with TP53 aberrations (n = 9), complex karyotypes (n = 6), NOTCH1 mutations (n = 2), or SF3B1 mutations (n = 4). Additionally, the modest number of CRs achieved by patients treated was in line with what was expected of B-cell receptor signaling inhibitors, Danilov explains. Finally, only one patient discontinued treatment because of toxicity, Danilov concludes.